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The resolution of [his court case only confirms our view [hat international mar-
kets, which play an increasingly important role in all our lives, have no inbuilt 
conscience. But governments and ordinary people acting collectively have a 
precious responsibility to make the huge companies that dominate the rn,arkets 
accountable for how they respond to the most critical issues of our times." 
I INTRODUCTION 
The relationship between law and social and political issues in South 
Africa has a long and rich history. Much of this history relates to the abuse 
of law and law-making to serve segregationist ends and the response of 
'progressive' lawyers to this.' Between 1907 and 1908. Mahatma Gandhi 
tried to use defiance of the law, and his position as an admitted advocate, 
to resist racist legal reforms being planned by the colonial government 
(the so-called Black Act). Then in the 1950s and 1 960s the African Na-
tional Congress (ANC) engaged legal strategies to try to resist and justify 
defiance of unjust laws.' This culminated in 1964 when Nelson Mandela 
and his co-accused used their defence in the Rivonia Trial to debunk some 
of the main tenets of apartheid and as a platform for advocacy and much 
I This paper was prepared for presentation at Health. Law and Human Rights: Exploring 
the Connections, An lnternalional Cross-Disciplinary Conference Honoring Jonathan M. 
Mann. September 29 - October I. 200 I. Philadelphia. Pennsylvania. The author ac· 
knowledges the assistance of Zackie Achmar. Gilbert Marcus and Marlise Richter for 
their suggestions on earlier drafts. 
2 Media Statement. Dr Manto Tshabalala·Msimang. Minister of Health. 19th April 2001. 
3 See Chanock. 200 I: Corder. H (ed) 1998. 
4 "[DJuring these years the legal arena itself became a kind of politics. crucial to rhe very 










































LAW, DEMOCRACY &. DEVELOPMENT 
of the international mobilisation against apartheid that took place during 
the 1970s, 1980s and 1990s.5 
For a decade after the imprisonment of Mandela and most of the rest of 
the ANC's senior leadership, internal opposition that used the law to 
challenge apartheid shriveled, in tandem with the collapse of most politi-
cal opposition. It never died entirely and a number of lawyers, amongst 
them post-apartheid South Africa's first Minister of Justice Dullah Omar, 
remained in South Africa in what Omar described as "very dark years" 
using the law routinely to defend "hundreds and hundreds of people over 
the years on charges of contravening Pass Laws or workers who were 
charged with having gone on strike." " However, in the dying days of 
apartheid, on the crest of an enormous social mobilisation revitalised by 
the industrial working class and urban youth, law was again used exten-
sively this time to defend a new generation of detainees from arbitrary 
arrest and torture, as well as more boldly to challenge some of the fun-
damental tenets of apartheid law and practice, such as the Pass Laws and 
the Group Areas Act. One of the most significant developments during this 
period was the beginning of the use of law pro-actively to challenge injus-
tices and to mobilise public opinion. Ironically, public impact litigation in 
the 1980s and early I 990s found ways to turn defence into attack and 
thereby to rum apartheid's own laws on itself, exploit loopholes, and turn 
into de jure legal decisions what had often been made de facto by political 
struggle.' 
This tradition of pro-active use of law is the subject of this paper. It is 
linked to a perspective that - whilst not diminishing its core content and 
core value - imbibes law with extra legal purpose and potential. However, 
it differs from descriptions of law against apartheid in that it refers to the 
use of law in a different social and political environment. In South Africa 
today non-state actors, such as privately owned monopolies, are emerging 
as concurrent violators of human rights. There is increasing recognition 
that 'civil' rights, such as the rights to dignity and equality, are heavily 
dependent on the realisation of 'socio-economic' rights, such as access to 
health care services. This requires both a redistribution and equalisation of 
access to resources. However, in many spheres of life access to resources 
5 Mandela's 'ideal for which J am prepared [0 die' statement from the dock at the close of 
the Rlllonia trial became one of the great speeches defining black people's aspirations 
for equality. It is reprinted and quoted in numerous texts including Clingman 1998: 
314-315. 
6 Broun 2000: 237. Broun's interview with Dullah Omar reveals how. even in the most 
difficult of circumstances. law can be creatively used in the interests of the disempow-
ered. For example. Omar describes how he used the rules of criminal procedure, whIch 
allow evidence [0 be admitted in mitigation of sentence. to bring [0 Robben Island 
wives and relatives of political prisoners as witnesses. 'So we were able to beat the sys-
tem in many ways. That was very exciting.' 
7 This lInk between law and struggle is the subject of Richard Abel's book. Politics By 
Other Means: Law in the Struggle against Apartheid. 1980-1994. In a foreword, Geoffrey 
Budlender. reflects on the important but inherently circumscribed role of law in relation 
LO social change. by acknowledging that 'what breathed life into all successful legal work 










































DEBUNKING 'CONGLOMO-TALK'; A CASE STUDY OF THE AMICUS CURIAE 
is dependent on the co-operation of non-state actors, such as multi-
national companies, that are not governed by traditional human rights 
legi,,! 'In this context international Jaw, as much as national law, 
be COl (' subject of contestation. 
This artiCle focuses on the legal action brought by the Pharmaceutical 
Manufacturers' Association (PMA) to test the constitutionality of an 
amendment to South Africa's Medicines and Related Substances Control 
Act of 1965." It traverses some of the history of a case rich in irony, 
insofar as the PMA utilised rights in a Constitution that is primarily in-
tended to protect vulnerable people against vested interests. The irony 
was compounded when the Treatment Action Campaign (T AC) - a late 
joiner to the litigation - used the same rights-protections in the Constitu-
tion to turn the PMA's case against itself. eventually contributing to the 
cessation of the litigation by the PMA. 
The TAC's appropriation of the PMA case illustrates how legal action 
can be used to catalyse both national and international political mobilisa-
tion. Interestingly, the case acquired international significance without 
even culminating in a judgment. It shows how the diSCipline demanded of 
litigators can provide impetus for legal and social investigation. It can ass-
ist with the uncovering of facts that contest - and undermine - arguments 
of powerful vested interests that consciously masquerade as objective 
'truths' and 'rules' but whose origin often lies in political manipulation. 
power-broking and self-interest, rather than in reality or indeed in law. 
At the heart of the PMA case is the manner in which international law 
can be appropriated and written by forces with no formal law-making 
power, and then imposed upon governments. ~ As well as how this can be 
reversed. How the TAC and its allies achieved this is important to unpack 
and understand, because it offers a key to defence against one of the 
major strategies of human rights violators in the 'new world order' 
dressing rights-incursions in the language of rights-protection and using 
unlimited economic power to pursue legal strategies to consolidate this. 
This is not a new strategy. Summarising some of the uses of law against 
apartheid Richard Abel cautioned; 
As a sword. however. law may be ornamental or two-edged. Many victOries, 
legislative or Judicial, are largely symbolic, difficult or impossible to implemenr 
in practice. And vested interests may be better situated to invoke rights, de-
rived from the Constitution or natural law, in opposition to legislative or execu-
tive reforms, :0 
8 A fuller account of the evolution of the legislation. conflicts during the drafting process, 
and their aftermath is found in Gray, Matsebula, Blaauw. Schneider. Gilson 2001 
9 Accordin~:o Abbott 2000: "There is little mystery to the political economy of the TRIPS 
,'v_'!',,,'mciI: as it emerged from intergovernmental negotiations thar took place from the 
L', " '-,I, [0 the early 19905 This was a producer/technology-owner driven agreement. 
UEU) industry groups were in substantial measure able [0 avoid subjecting the negotia-
tions and agreement to close public policy analysis. Developing countries were encour-
[0 adopt the agreement by rrade incentives, and were threatened with severe 
sanctions for failing to do so." 










































LAW, DEMOCRACY & DEVELOPMENT 
In a similar vein, in May 1997 Dullah Omar, then the Minister of Justice 
used the first conference of the South African Human Rights Commission 
(SAHRC) to warn: 
Because of the imbalances we have inherited, only a few people have the ca-
pacity to enjoy their rights and the danger we face is that the Bill [of Rights] will 
be the sole preserve of the rich and powerful. II 
Public-impact litigation should evolve with changing socio-political cir-
cumstance, Thus, the TAC's intervention in the PMA case, rather than 
attempting to emasculate state power, aimed to assist the government to 
defend its right to pass legislation to fulfill its constitutional obligations to 
progressively realise rights of access to health care services. It represented 
a strategic intervention into circumstances where although the new 
democratic government has political power, a great deal of economic 
power remains in non-state hands, limiting the ability of the state to 
address scarcity in health. 
The full history of the case, and the legal issues it traversed, is lengthy 
and complex. Therefore, scrutiny will begin with the point when the T AC 
began to seek admission as amicus curiae in January 200 I. However, 
before this, it is necessary to first provide a context for the court drama. 
2 DE·CONSTRUCTING APARTHEID: IMPROVING ACCESS 
TO HEALTH CARE SERVICES 
Making health care more accessible to South Africa's poor is a constitu-
tional duty facing the government. In section 27 the South African Consti-
tution states: 
(I ) has the right to have access to -
(a) health care services, including reproductive health care; 
(bl 
(2) The state must take reasonable legislative and other measures. within its 
available resources, to achieve the progressive realization of each of these 
rights. 12 
This is not an easy responsibility to fulfill As with so many other spheres 
of life, the health system that the new South African government inherited 
in 1994 was racially divided and unequal On the one hand there was/is a 
private health sector, composed of highly paid doctors and modern medi-
cal facilities. This sector serves 20 % of the population (mostly white) but 
accounts for 80 % of national spending on health. On the other hand there 
is the public health sector, where 80 % of the population seek care (mostly 
black) - but where only 20 % of health expenditure takes place. 
In South Africa, as well as in the rest of the world, systems of private 
and public health care operate along parallel lines. But they are not inde-
pendent of each other. If private care is excessively expensive more 
1 I Quoted in Heywood and Cornell: 77. 
12 Constitution of the Republic of South Africa Act 108 of 1996. In addition s 237 requires 










































DEBUNKING 'CONGLOMO-TALK': A CASE STUDY OF THE AMICUS CURIAE 
people are dependent on public hospitals. Similarly, if doctors and nurses 
are highly paid in the private sector, then health workers are sucked away 
from public facilities.;' The Constitutional duty to improve access to health 
care services thus dictates not only that government invest in public 
health but also that it address distortions in the private sector. In essence, 
making pUblic health care more accessible means making private health 
care more affordable and efficient. 
The market for medicines in South Africa became grossly distorted un-
der apartheid. A first-world regulatory authority oversaw the registration 
of medicines and guaranteed their safety and efFicacy but it had no 
control over prices." The emergence of a substantial 'whites-only' private 
health sector, funded largely by medical insurance schemes. meant that 
medicine sold to [his part of the market could be highly priced - and 
highly profitable. Even during the years of apartheid this was recognised 
to be a problem. particularly by health providers: several commissions 
were set up to investigate the barriers to wider use of quality generic 
medicines - but their recommendations for legal reforms to permit wider 
use of generic medicines were thwarted by [he pharmaceutical industry. 
For example. in J 984 the South African Pharmacy Board amended its 
ethical rules and Government Notice R2525 gave pharmacists permission to 
substitute items on a medical prescription without the prior permiSSion of 
the prescribing doctor. This was challenged in Coun by the drug compa-
nies and the SA Pharmacy Board lost the case. Ten years later. in 1995. 
the South African Pharmacy Council repeated its support for generic 
substitution of brand name medicines on the grounds that it would "un-
doubtedly assist the community pharmacist to provide a more affordable 
pharmaceutical service to the public, thereby improving the accessibility 
of community pharmacy without compromising quality .. " a pOSition 
that was supported by the Pharmaceutical Society of South Africa (PSSA). 
The historic absence of regulation of medicine prices, and perverse 
practices that evolved in the dispensing and supply of medicines, permit-
ted very high prices to be set For medicines sold by private doctors. clinics 
and hospitals. 10 This Fuelled general medical inFlation which reinforced 
barriers to wider access to private care. 
13 The 1998 SA Health Review (Health Systems Trust) reports that "most recent graduates 
are employed in the publIc sector. and 77% of all doctors who qualified in the previOUS 
five years are working in this sector. In contrast 10 years following qualification. the 
majority are working in the private sector" (pi 50). 
14 The Medicines Comrol Council (MCC) was established in 1966. after the promulgation of 
the Medicines and Related Substances Control Act 101 of 1965. 
15 The Snyman Commission. 1959-1962: The Steenkamp Commission. 1975-1978: The 
Browne Commission. 
16 In the Answering Affidavit of the Director General. on behalf of the Minister of Health, 
the Amendment Act's introduction of a single exit price was justified on the grounds 
that whilst volume discounts were permined on medicines "there is very little evidence 
that these are passed on to (he consumer. This is because (he current system allows the 
distributors. wholesalers and retailers to make a profit on medicines and appropriate 
these discounts into profits and not pass (hem on to the consumer". Answering Affida· 










































LAW, DEMOCRACY &, DEVELOPMENT 
In the public sector most patented medicines were unaffordable. Fur-
ther, generic medicines, although sold at prices greatly lower than to the 
private sector. were still sold at prices that the South African government 
would allege in its legal papers to be substantially above what was normal 
in many other countries. i7 
Racial discrimination in access to health care services was thus exacer-
bated by economic discrimination that favoured the wealthy. This situa-
tion was carried over into post-apartheid society and, some surveys 
suggest. has got worse. For example in 1999, 66 % of people surveyed by 
the Community Agency for Social Enquiry (CASE) said "cost" was their 
main reason for not seeking health care when they were sick. In the same 
survey 40 % of African respondents said that access to medicines had "got 
worse"." 
Tackling these distortions and their consequences reqUires a variety of 
strategies. To this end a range of policies and laws have been introduced 
since 1994.:0 For example, one objective of government health policy is to 
try to make private hospital care more affordable and thereby reduce the 
patient-load and the resource drain on the public sector. Thus the Medical 
Schemes Amendment Act, No. 131 of 1998 aims to make private health 
care more widely available by removing unfair barriers to membership of 
medical schemes and strengthening the regulations governing the indus-
try. 
Another area of focus was on the affordability and availability of medi-
cines. A tight-rope had to be constructed requiring careful balance. A 
National Drug Policy was published in 1996. Its aim is to rationalise the 
prescription and use of medicines through a variety of mechanisms, 
including a pared down Essential Drug List (EDL). Several legal mecha-
nisms to reduce the drugs bill were also suggested, induding encouraging 
generic substitution of off-patent medicines, the use of parallel importa-
tion and possibly compulsory licensing. 
It was hoped that the combination of these strategies would reduce the 
costs incurred in the purchase (by the state) and the prescription (by the 
17 Disputes about the price of medicines were a running sore between the PMA and the 
government even before this litigation commenced. See: Public Protector. Report No 6. 
"Repon on the Propriety of the Condue[ of Members of the Ministry and Department of 
Health Relating [0 Statements in Connection With the Prices of Medicines and [he Utili-
sation of Generic Medicines in South Africa". November 1997. 
18 The Second Kaiser Family Foundation Survey oj Health Care in South AJrica, Community 
Agency for Social Enquiry (CASE), August 1999. 
19 These were first set out in the White Paper for the Transformation of the Health System 
in South Africa. Government Gazene 17910. 16 April 1997. 
20 Under the Act schemes may not registered if they discriminate on grounds of 'state of 
health'. Prescribed Minimum Benefits (PMBs) were introduced to provide a floor for 
health care provision. 
21 Parallel importation is the importation of a brand-name medicine under patent from a 
country where the patentee sells it at a lower price than in the local market. Compul-
sory licensing refers [0 the over-riding of certain patent rights by the licencing of a com-
petitor to produce and market a medicine that is still under patent Compulsory licens-
ing, in a limited number of circumstances and according to legally defined processes is 










































DEBUNKING 'CONGWMO-TALK': A CASE STUDY OF THE AMICUS CURIAE 
public provider) of medicines. The objectives: lowering the state medi-
cines bill whilst increasing medicine availability; decreasing the amount 
spent on medicines by private providers - so as to increase affordability 
of private care; increasing the amount of money available for other health 
services whilst simultaneously increasing the volume and public health 
value of medicines. 
It was with these obligations in mind that, on 31 October 1997, the Na-
tional Assembly passed the Medicines and Related Substances Control 
Amendment Act, No. 90 of 1997 (hereafter referred to as the Medicines 
Act)"' This law amended the Medicines and Related Substances Control 
Act, No. 101 of 1965 and contained a range of measures that aimed to 
make medicines more affordable and improve the functioning of the 
Medicines Control Council (MCC). 
The Act was fiercely opposed by the then Democratic Party (DP), New 
National Party (NNP) and representatives of the pharmaceutical industry. 
On 18 February 1998, the PMA and forty multinational drug companies 
filed a Notice of Motion and Founding Affidavit with the Pretoria High 
Coun and sought an interim interdict to prohibit the President and Minis-
ter of Health from bringing into operation crucial sections of the Amend-
ment Act, and declaring the sections unconstitutional. Many of the 
contested measures were already standard practice in developed coun-
tries and, prima facie, in compliance with international agreements such 
as that on Trade Related Aspects of Intellectual Property (TRIPS). In effect, 
the legal action was an attempt by the PMA to use the Constitution to 
annex additional powers and safe-guards for intellectual property that are 
not part of TRIPS; to fill in some of the ambiguities in TRIPS. particularly 
its vagueness around 'parallel importation'; and to warn other developing 
countries off a similar path. The Act was thereby stopped in its tracks. 
Between February 1998. when the PMA initiated legal action, and 10 
November 2000, when it set the matter down for hearing in 2001, a great 
deal happened politically. Although litigation had commenced. much of 
the substance of the dispute was thrashed out outside of the courts. For 
example. in 1998 pharmaceutical company lobbying was successful in 
having South Africa placed on the United States Trade Representatives' 
(USTR) 301 Watch List. A year later it was removed as a result of activist 
pressure, primarily in the United States, that led to then US President Bill 
Clinton signing an 'Executive Order' that recognised the rights of coun-
tries in Africa to pass legislation without interference from the United 
22 In 1996 South Africa developed a National Drug Policy (NDP) with the co-operation of 
till" pharmaceutical industry. where these objectives were set ouL 
23 TIl(· Nellional Council of Provinces passed the Medicines Act on 20 November 1997 and 
Prc·wir.'ni Mandela signed the law on 25 November 1997. 
24 Tilt pharmaceutical industry has been lobbying OECD governments to use the next 
round of world trade negotiations to strengthen TRIPS. or to create a "TRIPS-plus" 
agreement. These aims were thwarted by protests targeting the WTO meeting in Seattle 
in 1999 and will be more difficult in the wake of the global awareness that has devel-
oped around pricing policies amongst both governments and citizens. 
25 This period is analysed in detail in Gray, Matsebula, Blaauw. Schneider. Gilson 2001 










































LA W,.DEMOCRACY &, DEVELOPMENT 
States, as long as p was TRIPS-compliant,'t AIDS activism helped to cata-
lyse an internation,.d activist movement that challenged the impact of 
international trade law on social and economic rights (such as health). 
[n South Africa, the froth in international politics masked a stasis 
around the court papers. The pharmaceutical companies benefited by this 
inertia, The Ministry of Health lacked the capacity to respond timeously to 
the PMA's papers and this led to requests for postponements by the State 
Attorney, which were readily agreed to. The consequence of these post-
ponements was that measures which would have drastically brought 
down the price of many medicines (as well as their profitability) were 
delayed, saving the pharmaceutical companies many millions of dollars 
and delaying the advent of affordable health care in South Africa. 
This period had also seen the rapid emergence of an AIDS activist 
movement in South Africa with the launch of the TAC in December 1998, 
Between 1999 and 200 I, the T AC was aware of the issues in the court 
case and frequently engaged the PMA through demonstrations with de-
mands to withdraw the case, However, a lack of capacity delayed the 
TACs ability to tackle the issue squarely, Other campaigns were more 
aggressively pursued and alliances constructed, This helped prepare civil 
society in South Africa for the kind of mobilisation that would be required 
in the PMA marter,'c In 2000, the TAC waged a campaign against Pfizer 
Inc. to demand a price-reduction of its anti-fungal mediCine, Diflucan 
(fluconazole), The campaign reached a high-point in October 2000 when 
the TAC chairperson, Zackie Achmat. returned to South Africa from a trip 
to Thailand with 5000 tablets of a bio-equivalent generic fluconazole 
(Biozole) - and the TAC held a press conference to announce the com-
mencement of its patent abuse defiance campaign. This action led to 
intense public discussion about the morality of patent abuse and pricing 
of medicines. It dominated the news headlines for a week, and led to 
television and radiO discussions, Its effect was to educate the public and 
--~ ... ----
26 A Press Release of 17 September 1999 from the Office of [he USTR stared that the US 
and SA governments had "come to an understanding with respect [0 South Africa's ur-
gent need [0 provide better, more affordable health care while ensuring that intellectual 
property rights are protected." The limitation of the Executive Order was that it con-
fined itself to Africa, a problem that arguably emanated from the activist focus on the 
African AIDS epidemic to the exclUSion of [he needs of populations in other developing 
countries, particularly Asia and Latin America. 
27 Speaking in his personal capacity, Dr Wilbert Bannenburg. estimated that the delay in 
the advem of mandatory generic substitution could have saved the pharmaceutical 
companies up [0 R2 million per day. According to Dr Bannenburg, based on an annual 
private sector turnover of R7 blllion, of which up to 50% (R3,5 billion) are brand name 
medicines that fall into a 'substitutable target group', a savings of 10-20% on annual 
turnover was achieved by the industry by delaying the Act with litigation. This amoums 
to R350-700 million per year or RI-2 million per day. Personal correspondence, 29 
November 2001. 
28 A chronology of these actions was included in TAC's I st March 200 I Replying Affidavit 
responding to PMA claims that it was an organisation that lacked "substance" and 
which had failed to approach the Court according to time-frames set Out in the rules of 
Court. 
29 See Lewis 200 I (video history) and an overview of the history of TAe. written by 










































DEBUNKING 'CONGLOMO-TALK'; A CASE STUDY OF THE AMICUS CURIAE 
build sympathy and support for the TAC across the social and political 
spectrum.'v The campaign undoubtedly influenced the decision of Pfizer 
to donate Diflucan for use in the public sector by people with certain 
AIDS-related opportunistic infections. 
By early 2001 in the wake of successful advocacy to highlight the 
differentials between essential generic and patented medicines, particu-
larly fluconazole. the TAC was ready to intervene in the court case. On 10 
November 2000, the PMA had quietly set the matter down for hearing in 
March 200 I. Strangely, the South African government had not drawn 
public attention to this. This changed on January J 1 th 2000 when the 
PMA's Head of Scientific and Regulatory Affairs, Maureen Kirkman, in-
formed the TAC of the dates. Early in January a discussion was held with 
senior lawyers about whether the TAC should aim to join as a party. The 
TAC was advised that this would seriously delay the hearing. Therefore, it 
was decided to seek permission from the parties and the court for leave to 
intervene as amicus curiae. 
The TAC's first objective was to break the two year inertia and to draw 
international attention to the dates of the case. This it did on January 16th 
at a press conference where the TAC announced that it would seek to join 
as amicus curiae and simultaneously mobilise an international campaign 
to call on the pharmaceutical companies to withdraw from the matter. 
Thereafter, these two were pursued separately but at all times 
in close parallel to each other. Each benefited the other. 
2.1 Advocacy 
In one important respect the TAC intervention in the PMA case differs 
from public impact law under apartheid, After the Soweto uprising in 
1976 the social movement against apartheid revived independently of the 
law, but took advantage of the law and progressive lawyers to consolidate 
and catalyse change. After the political defeats of the early 1 960s very few 
lawyers were prepared to take on apartheid in the absence of a political 
movement. Many went into exile or were imprisoned. Their courage re-
turned with the return of political opposition. By contrast, although on an 
infinitely smaller scale at this stage, the TAC has used law and mobilisation 
30 A canoon in the Cape TImes depicted the Minister of Health standing beside a bed-
ridden person with AIDS. and two jars of medicines, one labelled 'Big Company AIDS 
Drugs SSS' and the other 'Cheap generic AIDS drugs courtesy of TAC' and "You 
can't have these because they're too expensive, and you can't have these 
they're illegal. Now is there anything else I can help you with?" to which the person re-
sponds "Oh ja I was wondering if it's Just coinCidence that 'Hippocratic and Hypocriti-
cal sound so similar?'" 
31 According to Rule 16A of the Rules of Court leave to join as amicus curiae must be 
sought within 20 days of the "filing of the affidavit or pleadings in which the constitu-
tional issue was first raised". However, this new rule was added in 2000 (GNR849 of 
2000), long after the PMA case had commenced. One of the major tactical errors of the 
PMA was to base much of its strategy on Withholding consent, This mistake allowed the 
TAC legitimately to present the PMA as wanting to keep the voice of affected people out 
of the hearing. It also became a strategic error in court, as the arguments made by the 











































concurrently, and has often been responsible for both. It has been aided 
in this by a Constitution with a clear Bill of Rights, and a legal tradition 
that encourages the use of litigation as a way of colouring in and defining 
its principles, 
There is also an important overlap between the two periods. The TAC 
draws much inspiration from the work of Edwin Cameron, one of the 
pioneers of public impact law in the 1980s. Senior Counsel for the TAC in 
the PMA case was Advocate Gilbert Marcus, who has had long involve-
ment with public interest law and in 1985 argued as amicus curiae in a 
case that led to the unbanning of the Freedom Charter. 
On 15 and 16 of January 2001 the TAC national executive committee 
(NEC) met in a clinic run by Medicins sans Frontieres (MSF) in Khayelitsha 
in Cape Town. Spirits and confidence were high, in the light of the impor-
tation of another batch of fluconazole tablets from Thailand (this time 
declared at customs by Morne Visser, a local TV actor), which were 
handed over to cheering activists at Cape Town International Airport in 
the glare of television cameras. The T AC knew that this was testing the 
legal boundaries of the exemption that it had received from the Medicines 
Control Council (MCC) in 2000 to import the generic medicine for use by a 
clinic in Cape Town. A resolution to try to intervene as amicus curiae was 
unanimously passed by the NEC32 and the TAC called for a Global Day of 
Action against the pharmaceutical companies on March 5th 200 I, the first 
day of the court case. This call received Significant attention from the 
local and international media. 
Between January and March mobilisation in South Africa and interna-
tionally was intense. The start of the court case was a focal point, but the 
legal process engaged in by the TAC to try to gain admission as amicus 
curiae gave it a day-to-day reality, and allowed the legal questions to be 
teased out into the public domain and to provide valuable public educa-
tion around the issues. 
On March 5th 5000 people, led by religious and trade union leaders, 
marched past the Pretoria High Court and handed a Memorandum over at 
the US Embassy. On March 4th COSATU and the TAC staged an all night 
32 Paragraph 2 of the resolution read: "TAC's participation should ensure a speedy process 
to remedy the collusive paralysis between the parties that have prevented this court 
case from being completed with the urgency that it deserves. In the period of its delay 
and counter-delays. more than 400,000 people have died of AIDS related illnesses ac-
cording to government." 
33 On 19 January 2001. TAC issued the following call: "lAC calls on people in every 
country to mobilise against drug company profiteering on Monday 5 March 2001. On 
this day, the action by more than 40 multinational drug companies against the South 
African government will be heard in the Pretoria High Court. Millions of people will die 
from HIVIAIDS and other illnesses. if the drug companies succeed in their action. lAC 
specifically calls on our allies Mectecins Sans Frontieres, HealthGap Coalition. AClSA 
and all the organisations who endorsed the Global March for HIVIAlDS Treatment Ac-
cess to mobilise. A victory for the drug companies in this case will set back the struggle 
for access to essential medicines in all countries. lAC will mobilise actions against drug 
companies throughout the week 5-12 March 2001." 
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vigil in a tent outside the Court, and the TAC leaders seized the rare 
opportunity to workshop the most senior officials of COSATU until 2 in the 
morning on legal and political issues posed by the case, 
Internationally the TAC formed alliances with Oxfam, MSF, Action for 
Southern Africa (ACTSA) in Britain and the Health-GAP coalition in the 
USA - several of these organisations were already campaigning against 
the pricing practices and abuse of patents by pharmaceutical companies, 
These allies were able to mount pressure directly against the companies 
as well as on the governments of industrialised countries. When the case 
began on March 5th, demonstrations were held in 30 cities world-wide, 
including in Brazil, the Philippines, the USA, Britain, Kenya, Thailand, 
France, Italy, Denmark, Australia, and Germany, By this point over 250 
organisations from 35 countries had signed a petition opposing the legal 
action. The civil society mobilisation, supported by international lumi-
naries such as John Le Carre, left the companies increasingly isolated. 
After the postponement of the case on March 6th, MSF initiated an inter-
national petition which collected 250 000 Signatures, and during this time 
played a crucial part in persuading the European Union and Dutch gov-
ernment to pass resolutions calling for the case to be dropped. 
During this period the media made great play of the 'alliance' between 
the TAC and the government - an alliance that drew criticism from some 
quarters on the left. It is important, therefore, to note the tensions behind 
this mobilsation. 
In reality there was little contact between the TAC and the government. 
On February I st a TAC/ALP delegation had met with the Director General 
of the Health Department, Dr Ayanda Ntsaluba, and discussed the case, 
The TAC received a positive response to its request to join as amicus 
curiae, although Ntsaluba explained that the final government pOSition 
would depend on consent from all the Respondents. This had to include 
the Office of the President, with whom the TAC has a very poor relation-
ship, largely as a result of the President's destructive public flirtation with 
the 'AIDS dissidents' and their views, Thereafter there was no direct con-
tact. Although the press were generally unable to grasp the point, the 
Ministry of Health understood that the amicus curiae intervention was but 
a stage in the TAe's campaign for treatment access, that would lay the 
foundations for intensified criticism of the government's policy concern-
ing access to treatments for HlV.3b Unlike COSATU, the African National 
35 This petition was published as a full-page advertisement in Business Day on 8 March 
2001. 
36 Pat Sidley, an experienced South African journalist. was well-aware of this, In a column 
For Business Day (23/04/2001) titled "Coun of PubliC Opinion" she wrote; "Alongside the 
pile of documents on my desk is a poster picked up at one of the TAC news confer-
ences. It is a picture of GlaxoSmithKline's CEO in SA. John Kearney, and it reads: 'AIDS 
profiteer. Deadlier than the virus: It infuriated and hurt him, Next to it is another TAC 
poster that carries ~ if you will the writing on the wall, It pictures Trade and Industry 
Minister Alec Erwin. Under his name the message reads: 'Issue compulsory licences, 











































LAW, DEMOCRACY &. DEVELOPMENT 
Congress (AN C) kept its distance from the T AC campaign. After victory 
had been secured the ANC excluded the TAC entirely from acknowledge-
ment. A 'victory rally' held in Church Square in Pretoria on April 19th left 
out the TAC completely and tried to elevate organisations that had en-
gaged very little with the case. Similarly, whilst the Minister of Health 
congratulated the TAC's international allies, such as Oxfam and ACTSA, 
she privately chided them for working with the TAC'? 
Leaders of the ANC and some Ministers expressed concern that the TAC 
had hijacked the case and turned all attention onto the question of access 
to antiretroviral drugs. Whilst the media might have contributed to this 
impression, a study of what the TAC actually said and wrote will not 
support this. 
The TAC's main arguments were that access to health is a human right 
that trumps rights to private property particularly when these rights are 
being abused. Specifically, the TAC argued that patented antiretroviral 
medicines (needed by millions in Africa) bear out the main contentions of 
the Respondents: that patents were being used to gouge prices. Some of 
the measures in the Act, specifically section 15C, could be used to bring 
down prices of patented medicines. However, as important to the TAC's 
argument was the impact that section 22F (the requirement for generic 
substitution of off-patent medicines) would have on making medicines 
that treat and prevent opportunistic infections more affordable - as well 
as the potential benefits for the health system as a whole. 
The mobilisation against the PMA and the other pharmaceutical com-
pany applicants was conscious and deliberate. Its success was not pre-
ordained. It came about as a result of creative advocacy, skilful interaction 
with the local and international media, and research. Critically important 
was the ability of the TAC and its international allies to win the argu· 
ments. 
2.2 The Treatment Action Campaign's approach to law 
The PMA's attack on the Act revolved around a handful of key issues. But 
as is the fashion of legal action whose objective is to delay and frustrate 
legislation (and where resources are limitless), the papers attacked almost 
every clause of the. Act, as well as the procedures by which it passed 
through parliament.'o For an amicus applicant to be admitted, the amicus 
has to show that it can provide insight and argument that does not already 
37 The only senior politician to mention TAC by name was Deputy-President. Jacob Zuma. 
who issued a statement that specifically commended TAC's role in the case. 
38 On this Pat Sidley wrote: "For many journalists of my Vintage. the activists were manna 
from heaven; they even invoked some nostalgia for the anti-apartheid struggle of old. 
They were always available. returned phone calls (most of them) and provided moun· 
tains of useful. interesting information. They were dealing with a series of complex 
medical and legal questions. and were always available to teach and explain. Pharma· 
ceutical companies. evasive and secretive at the best of times. retreated further into 
their shells." (Business Day 23/04/2001). 










































DEBUNKING 'CONGLOMO-TALK'; A CASE STUDY OF THE AMICUS CURIAE 
exist in the court papers - that its input is not erroneous, vexatious or 
repetitive. Unless special permission is sought, the amicus curiae must 
confine itself to points of law and not introduce new evidence that might 
be disputed. 40 Departing from the thrust of the international campaign 
which had rallied mainly around a defence of section 15C of the Act, the 
TAC decided to focus on three key sections (including 15C) and to use the 
need for medicines created by the HIV/AIDS epidemic to highlight why 
each of these measures was necessary and justifiable. 
The three areas were identified as sections 15C, 22F and 22G. They 
dealt with parallel importation, generic substitution and the establishment 
of a pricing committee. 
40 For example. in HOffman v SAA (2001 (1) SA (CO appealing Hoffman l'SAA (2000 (2) SA 
628 (W». the AIDS Law Project. which was admitted as amicus. sought special permis-
sion under 9(8) of the Constitutional Court Rules [(1 introduce evidence from .t\. v SAA. 
Labour Coun J 1916199 on the grounds that it contained information that was "relevant 
!O the determination of the issues" before the Court. 
41 ISC. Measures to ensure supply of more affordable medicines. The Minister may 
prescribe conditions for the supply of more affordable medicines in certain circum-
stances so as !O protect the heal(h of the public. and in particular may 
(a) notwithstanding anything !O the contrary contained in the Patents Act. 1978 (Act 
No. 57 of 1978). determine that the rights with regard !O any medicine under a pat-
ent granted in the Republic shall not extend to acts in respect of such medicine 
which has been put onto the market by (he owner of the medicine. or with his or 
her consent; 
(b) prescribe the conditions on which any medicine which is identical in composition. 
meets the same quality standard and is intended to have the same proprietary 
name as that of another medicine already registered in the Republic, but which is 
imported by a person other than the who is the holder of the registration 
certificate of the medicine already and which originates from any site of 
manufacture of the original manufacturer as approved by the council in the pre-
scribed manner, may be imported: 
(c) prescribe the registration procedure for. as well as the use of, the medicine referred 
to in paragraph (b)" 
22F. Generic substitution 
(1) Subject to subsections (2). (3) and (4). a pharmacist shall 
(a) inform all members of the public who viSit his or her pharmacy with a prescrip-
tion for dispensing. of the benefits of the substitution for a branded medicine of 
an interchangeable multi·source medicine; and 
(b) dispense an interChangeable multi·source medicine instead of the medicine 
prescribed by a medical practitioner. dentist. practitioner, nurse or other person 
registered under the Health Professions Act. 1974, unless expressly forbidden 
by the patient to do so. 
(2) If a pharmacist is forbidden as contemplated in subsection (I) (b), that fact shall be 
noted by the pharmacist on the prescription. 
(3) When an interchangeable multi-source medicine is dispensed by a pharmacist he or 
she shall note the brand name or where no such brand name exists, the name of 
the manufacturer of that interChangeable multi-source mediclfle in the prescription 
book. 
(4) t\ pharmacist shall not sell an interchangeable multi-source medicine -
(a) if the person prescribing the medicine has written in his or her own hand on 
the prescription the words' no substitution next to the item prescribed; 
Ib) if the retail price of the interchangeable multi-source mediclfle is higher than 
that of the prescribed medicine: or 
Ic) where the product has been declared nor substitutable by the council. 










































LAW. DEMOCRACY &. DEVELOPMENT 
On January 26th 2001 letters were sent to the Applicants and the Re-
spondents. seeking their consent for the T AC to act as amicus curiae. The 
TAC offered not to "burden the Court ... with additional evidence" and 
only to use "uncontroversial scientific facts pertaining to the H[V/AIDS 
epidemic and the role of medicines in the management of this epi-
demic ... ,,43 This offer formed part of the TAC's legal strategy which anti-
cipated that neither party would dispute published epidemiological reports 
about the HIV epidemic. and that the companies were unlikely to question 
the efficacy of their products. If undisputed, these two admissions would 
help to build a legal argument to justify the contested sections of the Act. 
For the TAC limiting the amicus' interest to three key provisions of the 
Act also helped with public education about the issues and forced the 
PMA to move into its terrain. 
The response of the attorneys for the PMA might. arguably. have been 
the turning point in the case. or the point at which the pharmaceutical 
companies began to lose control over its direction. Consent was withheld 
on a number of technical and substantive grounds. The T AC was advised 
to "reconsider, and thereupon abandon, [its] intended participation in the 
hearing of this matter" and "thereby avoid the expenditure of resources 
which could be better applied elsewhere." According to the PMA's attorney: 
The issues before the Court .. are of a constitutional nature and do not relate, in 
any way. particularly to access to Aids medication. The submissions which the 
TAC wish to advance .... , do not differ from the submissions of the other par-
ties to the application. No issues specific to the interests presented by the TAC 
and not equally applicable to other incurable diseases arise for decision in the 
application
H 
22G. Pricing Commitee 
(1) The Minister shall appoint such persons as he or she may deem fit to be members 
of a committee to be known as the pricing committee. 
(2) The Minister may. on the recommendation of the pricing committee. make regula-
tions -
(a) on the introduction of a transparent pricing system for all medicines and 
Scheduled substances sold in the Republic: 
(b) on an appropriate dispenSing fee to be charged by a pharmacist or by a person 
licensed in terms of section 22C (I) (a). 
(3) (a) The transparem pricing system contemplated in subsection (2) (a) shall include 
a single exit price which shall be published as prescribed. and such price shall 
be the only price at which manufacturers shall sell medicines and Scheduled 
substances to any person other than the State. 
(b) No pharmacist or person licensed in terms of section 22C (I) shall sell a 
medicine at a price greater than the price contemplated in paragraph (a). 
(c) Paragraph (b) shall not be construed as preventing a pharmacist or person 
licensed in terms of this Act to charge a dispensing fee as contemplated in sub-
section (2) (bJ. 
(4) The members of the pricing committee who are not in the full-time employment of 
the State may be paid such remuneration and allowances as the Minister. with the 
concurrence of the Minister of Finance, may determine. 
42 The T AC's legal team at the AIDS Law Project included attorneys Anita Kleinsmidt. 
Teboho Motebele and Advocate Liesl Gerntholtz. Counsel for the TAC were Matthew 
Chaskalson and Gilbert Marcus, Sc. Outside of the formal team the TAC benefited from 
the advice of Daniel Alexandra QC and Jonathan Berger. 
43 Ms A Kleinsrnidt. ALP attorney. leuer to State Attorney, 26 January 2001. paragraph 7. 










































DEBUNKING 'CONGLOMO-TALK': A CASE STUDY OF THE AMICUS CURiAE 
This response set parameters for the core arguments that would be made 
in the TAC's legal papers, as well as in its advocacy. If the PMA's conten-
tions could be disproved, it also created the unique angle needed to justify 
admission as amicus curiae. The challenge was to show (a) how the meas-
ures in the Act did have bearing on AIDS medicines and (b) how the cons-
titutional questions were not limited to those being posed by the PMA. 
Neither challenge was too difficult. The TAC was also assisted when on 14th 
February 200 I the State Attorney wrote that "our clients have con-
sented .. " 
Before looking at substantive legal arguments, it is important to draw 
attention to the manner in which, from the outset, the amicus application 
functioned simultaneously as legal argument and advocacy tool. 4o 
One of the TAC's objectives was to turn a dry contest into a matter 
about human lives - this was important for education of the court, as well 
as for public opinion. Thus, the TAC's main affidavits were deposed to by 
Ms Theodora Steele, the Campaigns Co-ordinator of South Africa's largest 
trade union federation, the Congress of South African Trade Unions (CO-
SATU), which has nearly two million members. This served two purposes: 
it made an ordinary person, with real interests in the legislation, the 
deponent, and it gave COSATU a sense of ownership in the court battle. 
The ability to mobilise thousands of people depended very heavily on the 
close support of COSA TU 
Similarly, reviving a tradition exploited by lawyers under apartheid of 
utilising affidavits as legally sanctioned instruments to tell the stories of 
lives affected by apartheid,'" twelve poignant affidavits were collected 
from people living with or affected by H IV47 , two from doctors treating 
people with HIV4s, and one from the Head of Mission of Medicins Sans 
Frontieres (MSF) in South Africa. 4 " These affidavits offered personal testi-
mony about living with HIV or AIDS in the shadow of medicines that are 
available but not affordable. They were all attached as annexures to the 
Founding Affidavit. 
---_ ........... _-
45 This was nor a new strategy either in South Africa or elsewhere, but it was a 
with innovations. For example. assisted by the communications revolution that 
taken place since the end of apartheid. TAC ensured that within hours of being served 
on the parnes and filed, all of its legal papers were placed on the TAC web-site where 
they could be accessed by journalists and activists alike. Unfortunately, despite the 
availability of legal papers, journalists across the world continued to misunderstand the 
nature ofTACs intervention and the AC[ itself 
46 Marcus 200 I. In his paper Marcus describes how a test case opposing the forced 
'resettlement' policy of the apartheid governmem (the Magopa case) enabled lawyers to 
"present to the world at large an extraordinarily moving picture of the history of the 
community spanning close to a century. That history was presented due to intensive 
field work done by Aninka Claassen who literally spent weeks living with the commu-
nity and learning their history. In that way, the plight of the community was presented 
in an accessible form to the world ... The case attracted international attention and the 
outcry which followed the removal effectively brought an end to forced removals," 
47 Mr Zackie Achmat; Ms Nomfundo Dubula; Ms Mkhanyiseli Mpalali; Ms Siphokazi 
Mthathi: Ms Helen Makebesana; Ms Ntornbozuko Khwaza; Ms Thandeka Mantshi; Ms 
Rose Peni; Ms Patricia Dove; Mr Vernon Ms Charlotte Mohapi; Ms Judith Ogle. 
48 Dr Leon Geffen and Dr Herman "Thernba" 










































LAW. DEMOCRACY & DEVELOPMENT 
The TAC's Founding Affidavit was filed on February 16th 200 I. It aimed 
to establish that the AIDS epidemic did create an emergency in which the 
need for more affordable medicines is a matter of life and death for 
millions of people. Even if the Act had not been devised with the AIDS 
epidemic specifically in mind (which it had not: its objective was to make 
all medicines more affordable) the epidemic created urgency and justifica-
tion for legal measures to make medicines more affordable. 51 Contrary to 
what was suggested in Vermaak's letter the number of people with HIV, 
and the excessive price of HIV-related medicines meant that the amicus 
did have issues to raise that were not "equally applicable to other incur-
able diseases ... 52 
The architecture of the T AC's Founding Affidavit is worth describing. An 
expert aFfidavit from a specialist HIV clinician, describing a range of the 
medicines that are used to fight HIV or its symptoms, was annexed in 
order to subtly challenge the applicants to dispute the efficacy of their 
products (which of course they did not) 53 With the safety and efficacy of 
the medicines and the scale of the HIV epidemic placed beyond the realm 
of dispute, it would be possible to concentrate the court's attention on 
how the price of medicines was the major barrier to access, and thus the 
justification for the measures in the Act, should it be found that they did 
limit the rights to property of the pharmaceutical companies. 
A Founding Affidavit is intended to convey evidence. rather than legal 
argument which is saved (under South Africa law) for presentation in 
'Heads of Argument' (submitted shortly before the hearing) and in oral 
argument on the papers before the Court. However, the Founding Affidavit 
must, obviously, lay the eVidentiary foundations For the legal argument. 
The T AC' s legal argument was that none of the three contested clauses 
was unconstitutional. Indeed, the T AC argued that they were dictated by a 
positive duty on the government [0 "progressively realise" ri~hts of access 
to health care services and to protect rights such as dignity,O; life,55 equal-
ity'0 and the duty to act in the best interests of the child"7 - rights which 
--_ .... _--
50 Stress was placed on the emergency caused by the HIViAIDS epidemic in order to 
prepare for legal arguments that any limitation of property rights could be justified on 
the grounds that it was for a "public purpose or in the public interest" [SA Constitution, 
s 25(2)(a)). as well as in keeping with the TRlPS agreement which allows for expropria-
tion (in the form of compulsory licensing) "In the case of a national emergency or other 
circumstances of extreme urgency" [TRIPS. Article 31, (f)J. 
51 The TAC Founding Affidavit stated at para 80 "Generic substitution will benefit all 
members of the public who rely on private sector care. However, people with HIViAIDS 
who need treatment for opportunistic infections ... will benefit directly through access-
ing lower cost, good quality generics." 
52 To establish this point the amicus annexed South Africa's 1999 and 2000 ante-natal 
survey, reporting an estimated 4,7 million HIV infections, as well as a December 1999 
speech by UN Secretary General Kofi Annan at the launch of the Internanonal Partner-
ship Agall1st AIDS in Africa. 
53 Expert Affidavit of Dr David Johnson 
54 Constitution on the Republic or South Africa, slO> 
55 Ibid. s II 
56 Ibid. s 9. 










































DEBUNKING 'CONGLOMO-TALK': A CASE STUDY OF THE AM1CUS CURIAE 
are dependent on measures to improve socio-economic conditions. 58 Poor 
people, the TAC alleged, were: 
directly dependent on the State's ability to fulfill its constitutional duty to bring 
about the progressive realisation of their rights of access to health care services. 
(FA, paragraph 13) 
However, in view of its limited resources, large epidemics such as HIV and 
TB, and the high price of medicines generally: 
the South African Government is constrained in its efforts to provide adequate 
and good quality treatment for its citizens who are dependent on government 
hospitals and clinics. (FA, paragraph 54, quoting from a 'Memorandum of 
Agreement between the South African government and Pfizer Laboratories ltd', 
1 December 2000) 
The law is an attempt to overcome these constraints. The T AC argued that 
it was not a violation of TRIPS, pointing out that measures such as manda-
tory or incentivised generic substitution of off-patent medicines are com-
mon practice in industrialised countries. I n the event that aspects of the 
Act might be found to be unconstitutional, the TAC argued that under 
South Africa's Constitution certain rights may be limited as long as the 
infringements are "reasonable and justifiable in an open and democratic 
society based on human dignity, equality and freedom".5' The TAC argued 
that should any of the Act's measures be found to limit property rights, 
these could be justified on the grounds of the government's obligations to 
improve access to health care services, as well as other duties arising from 
international treaties: 
The government of South Africa is Justified in seeking to avoid the massive so-
cial and economic disruption caused by the H IV epidemic - and other causes of 
illness - by limiting the rights of the patent-holders to make excessive profits 
from the sale of the drugs in South Africa. (FA, para 71) 
Finally the T AC provocatively attacked one of the main tenets of the 
PMA's legal and media case: that the Act was a violation of intellectual 
property rights that would rob private investors of just rewards for inven-
tion and research, and thereby undermine preconditions for future re-
search into disease and medicine. 
The research and development costs borne by the applicants have been re-
couped many times over. The Amicus Applicant has on a number of occasions 
challenged, for example, Glaxo Wellcome, one of the applicants, and Pfizer, a 
member of the First Applicant to state what its R&D costs are in relation to anti-
retroviral and other drugs. The information was never provided. (FA, para 83) 
58 In this line of argument TAe can claim support of the President of the Constitutional 
Court" ... how can there be dignity in a life lived without access to housing, health care, 
food. water or in the case of persons unable to support themselves. without appropriate 
assistance7 But social and economic policies are pre-eminently policy matters that are 
the concern of government In formulating such policies the government has to con-
Sider not only the rights of individuals to live with dignity, but also the general inte-
rests of the community concerning the application of resources. Individualised justice 
may have to give way here to the general interests of the community." See Chaskalson 
2000. 










































LAW, DEMOCRACY & DEVELOPMENT 
The Founding AFfidavit listed a number of medicines essential for the 
treatment of HIV and its opportunistic infections, and tempted the PMA 
bear to come out of its lair and do battle on where they originated From, 
and how much public and private money was invested in them, They did 
JUSt that. 6D 
2.3 Proceedings in court 
The TAC's Founding AFfidavit, together with the mobilisation described 
above, shifted the core of the case irreversibly into territory the PMA were 
anxious to avoid. Retrospectively it is clear that the PMA's legal advisers 
erred in seeking to deny the TAC the right to be amicus curiae on legal 
technicalities." This was evidenced by the approach adopted by Myreana 
Deeb, the CEO and main deponent on behalf of the PMA, whose Answer-
ing AFfidavit replied to the TAC's submissions on the legal basis for 
cheaper medicines in the Following way: 
23.1 The question of whether medicines specific to treatment of 
HIV!AIDS related diseases are "expensive" or "cheap" or can and should 
be less expensive, also does not arise for deCision in the main applica-
tion. 
23.2 The present application is not concerned With the determination of 
priorities by the State, the role to be played by the State in addressing 
the AIDS epidemic in South Africa, or by the impact of socio-economic 
realities on the healthcare system. The Honourable Court will also not be 
asked to determine the identity of those responsible for the research 
and development of specific medicines .. whether research was 
funded by individual companies or by foreign government agenCies is 
wholly irrelevant to the main application. 
On March 5th and 6th 200 I, Deeb's assertions were vigorously interro-
gated and then rejected by the Coun. In the space of a few hours Advo-
cate Fanie Cilliers, Senior Counsel for the PMA, moved from arguing that 
the TAC had 'nothing new to bring to the court', to claiming that the 
argument of 'justification' was entirely new and that a 'minimum of Four 
months' would be required to give the applicants 'a Fair opportunity to PUt 
up evidence to reply to argument about justification.' Judge Ngoepe was 
unconvinced, stating at one point that 'this is a matter of public impor· 
tance not just the Respondents but people all over the world want a 
conclusion.' On March 6th he ruled: 
I am aware that the entire nation is interested and many people beyond our 
boundaries .... I have considered the submissions and come to the conclusion 
that, given the importance and fact that an order may have implications to 
60 This is not a new legal strategy. and again parallels can be found in the use of law under 
apartheid. In his biography of Bram Fischer. Stephen Clingman described how. despite 
the focus of historians on the political ethos surrounding the Treason trial "the essential 
drama... was a legal one. . the initial brilliance of the defence was that in all their 
harrying, pestering and baiting, they succeeded in shaping a case they knew they could 
win." See Clingman 1998. 
61 These included challenging TAC to prove that it was an "organisation of substance". 
demanding TAe's constitution and questioning the medical credentials of Dr Eric Goe-










































DEBUNKING 'CONGLOMO-TALK': A CASE STUDY OF H1E AMICUS CURIAE 
every citizen in this country, I therefore rule that the TAC be admitted as ami-
cus curiae. I also rule that the TAC is restricted to base and argue its case on the 
affidavit delivered with its Notice of Motion, subject to the right to reply ,,2 
The PMA was given until March 28th (three weeks) to answer the amicus 
curiae's Founding Affidavit. Thereafter, the Respondents and amicus were 
given until April 10th to respond to the Applicants. The matter was post-
poned until April 18th. The TAC's campaign to debunk and defeat 'con-
glomo-talk' now entered a new phase; perhaps best described as one of 
intensive research and investigation to refute the predictable response of 
the PMA. Further success now depended on the ability to marshal national 
and international research expertise into a final affidavit - in just over a 
month. 
2.4 Investigation: Replying to the PMA's Answering Affidavit 
On March 7th a legal strategy meeting was convened with the TAC's 
lawyers. the ALP. MSF and James Love, director of the Consumer Project 
on Technology (CPT). Immediately after this the TAC began to contact 
experts to depose supporting affidavits that would confirm and illustrate 
the main theses in the TAC Founding Affidavit and contradict the PMA's 
anticipated reply. Amongst those who agreed were Professor Andy Gray. a 
lecturer in pharmacology at the University of Durban Westville; Alex van 
den Heever, a health economist working with the Council for Medical 
Schemes; Prof Coleen Flood, a lecturer in law at the University of Toronto 
in Canada; Carmen Perez from Medicins sans Frontieres, and James Love. 
Discussions were also entered into with the Brazilian and Phillipine gov-
ernments to try to persuade them to depose affidavits dealing with state 
practice in their countries. Areas for research and the collection of further 
evidence were also identified. 
When it came, the PMA's Answering Affidavit was indeed predictable -
and once again careless. Its arguments were clumsy and, given the re-
sources available to the PMA, surprisingly poorly supported. An affidavit 
of 52 pages, deposed to by Deeb, was supported by annexures of 500 
pages, mainly made up of pamphlets produced by the International Fede-
ration of Pharmaceutical Manufacturers Associations (IFPMA) - described 
by one TAC member as 'the collected works of Harvey Bale' (the Director 
of the !FPMA). Bale could hardly be described as an independent expert. 
Essentially the PMA grouped its reply into four major themes. The 
PMA's first argument was that the extent of poverty in South Africa means 
that for millions of people any price for medicine is unaffordable: "this 
consideration is relevant to an argument relating to the state supplying 
medicines free of charge to such people and funding the cost thereof from 
general taxation." Oddly, Deeb thus deduced that this was "the only 
context, in which the constitutional obligations of the state (Section 7 (2) of 
[he Constitution) are relevant." In a related jump in logic Deeb then 
62 Personal notes taken in Court (not the official Court record). 










































LAW, DEMOCRACY &. DEVELOPMENT 
alleged that the TAC's arguments to justify measures such as generic 
substitution that would lower prices would benefit only a minority of 
people with HIV!AIDS who could afford to purchase medicine and use 
private sector health care (ie. people who were not the state's responSibil-
ity). This latter category was estimated by Deeb to be in the region of 0.84 
million - too 'small a number' of potential beneficiaries to be justification 
for far-reaching infringements on intellectual property rights . 
. the real of patients with HIV/AJOS actually seeking or receiving medi-
cal treatment in the private sector probably stands at well below I % of the 
population The justification argument thus reduces to a relatively small sector 
servicing patients In the group that can best afford medicine, and to part of the 
sector in which the applicants need to recoup expenses and make profits (inter 
alia to enable them to continue to cross-subsidise the cheap medicines supplied 
to the public sectorl.
t4 
The TAC's response to this was to point to the inter-connectedness of the 
private and public health services, how the policies of one impact directly 
upon another, and how many people who are poor seek care from both 
sectors. Sister Susan Roberts, an infectious diseases sister at a johannes-
burg hospital. provided an affidavit describing her experiences of the 
cross-over between the public and private sectors in a major tertiary 
hospital. She explained how when a hospital pharmacy "does not have 
the prescribed medicine available (ie. because the medicine is not on the 
essential drug list usually because of cost)" patients are given a prescrip-
tion to be taken to a private chemist. In a particularly damning comment 
she reflected on how: 
In my opinion, decisions on what medicine to prescribe are sometimes made 
that are not in the best interests of the patient because of budgetary consuaints 
that might face the hospital and the patient. (R.oberts, 15) 
The second PMA argument repeated tired assertions about the role of 
private investment in research and development (R&D), and the need to 
encourage and protect this investment through patent protection: 
If no encouragement in terms of reasonable financial returns on the required 
investment is to be allowed to the research-based multi-national pharmaceuti-
cal industry, the motivation for the search for a solution for this disease will 
disappear. Then the only remaining scenario is that the disease will find its own 
end: the funeral of the very last carner of the virus. (7.2.14) 
Here the TAC relied heavily on the expert evidence of James Love, which 
detailed the real costs of research into new medicines; how these are 
shared by governments and the private sector; and the profitability of the 
pharmaceutical industry.6t. As a result of an important collaborative investi-
gation with students at the Universities of Minessota and Yale, the TAC was 
also able to describe how the compounds for two important anti-retroviral 
64 Ibid, 4.2.5 (d). 
65 Affidavits oFvan den Heever. Gray and Roberts (see wwwtac.org.za). 
66 GlaxoSmithKline's 'Preliminary Announcement of Results for 2000' was annexed, as 
was a report by reputable US consumer group, Public Citizen. dealing with the profit-










































DEBUNKING 'CONGLOMO-TALK'; A CASE STUDY OF THE AMICUS CURIAE 
drugs, d4T and abacavir, were discovered and developed with public 
funds at these universities and later licensed to Bristol Meyers Squibb and 
Burroughs Wellcome respectively.o, 
The third PMA argument was that, if the TAC's interest was with AIDS 
drugs, the legislation and thus the amicus was unnecessary because price 
discounts on medicines had been offered to the South African govern-
ment. The PMA's Affidavit then proceeded to detail and annex correspon-
dence concerning all the offers that had been made. By doing this, the 
PMA called the SA government's bluff, in so far as the government had 
repeatedly denied that any concrete offers had been made. But in doing 
so it publicised, for the first time, what prices were being offered as well 
as the nature of those offers. 
Although of little assistance to the PMA's legal argument (the TAC 
pointed out that charity did not "do away with the need for national 
legislation that aims to ensure all citizens sustainable access to essential 
medicines"O'\ this information was extremely valuable to the TAC, and to 
the cause of treatment access in South Africa. It provided a new platform 
for advocacy and was one of the most tangible gains of the litigation. 
After the conclusion of the case the TAC called for the price reductions to 
be extended ro the private health sector, and launched a campaign to this 
effect targeted at Bristol Meyers Squibb. After some half-hearted excuses 
about why this was not possible the prices were lowered across the board. 
Effectively, within the period of the TAC intervention the cost of triple-
combination antiretroviral therapy in South Africa was reduced from 
approximately R3,000 per month to R 1,500 per month. Although still way 
beyond the affordability of most people this holds out the prospect of a 
significant expansion of drug access in South Africa. 
Finally, the PMA used its affidavit to re-state its claim that the legislation 
made the South African government a pariah state. Listing 150 countries 
that were co-signatories to TRIPS with South Africa (including Zimbabwe, 
Columbia, the United Arab Emirates, Pakistan, Brunei), and insisting that 
"most of these countries are open and democratic societies based on 
human dignity, equality and freedom" it claimed that "it will not be possi-
ble for the amIcus to point to one other such country from the list cited 
above of which the legislature has passed legislation which ... 
9.1.14.5.1 Provides for the notion of exhaustion of patent rights, or for the 
permissibility of parallel importation in the terms utilised in section 
15C and I (4) of the 1997 Act; 
9.1.14.5.2 Provides For generic substitution of prescribed medicine in terms of 
the mandatory terms (Sic) and with the lack of administrative pre-
scnption Found in the wording of section 22F of the 1997 Act; and/or 
9.1 14.5.3 Provides for pharmaceutical cost containment in the manner and 
fashion as set out in section 22G of the 1997 Act: 
South Africa stands alone." 
67 TAC Replying Affidavit (Steele), paragraphs 36,36. J &. 36.2. 
68 An internal Memorandum of the TAC detailIng the price reductions is proVided as 
annexure C. 










































LAW. DEMOCRACY &. DEVELOPMENT 
This was not a difficult challenge to rise to. The T AC was able to annex 
affidavits by two experts describing the practice of generic substitution in 
many other countries (including the USA) as well as to provide informa-
tion about the legal approach to medicine price control in the United 
States. United Kingdom, Canada, Brazil and the Philippines. Direct discus-
sions were entered into with the Philippine government and, had the PMA 
not withdrawn the case, the TAC was preparing to put into the record an 
affidavit from the former Secretary of Health, Dr Alberto G Romualdez, 
explaining Administrative Order 85, a regulation used by the government 
of the Philippines to parallel import medicines from India. 
The TACs Heads of Argument, drafted by Advocates Matthew Chaskal-
son and Gilbert Marcus, SC, were filed on 17th April 2001. If the Replying 
Affidavit made rubbish of many of the 'factual' assertions of the PMA, the 
legal argument removed all vestiges of reasonableness concerning their 
allegations of rights violations. The TACs legal team identified what they 
described as 'a weakness that lies at the heart of much of the applicants' 
case.' This was the manner in which the PMA depended upon an argu-
ment that the measures lacked rationality because they were 'over-broad', 
'ambiguous' and 'over-shot the mark: The TAC replied that a rationality 
review reqUires only "that the legislation has a purpose that is not uncon-
stitutional and that it is rational to believe that the legislation will advance 
this purpose." 71 For example, section 217 of the Constitution requires that 
when an organ of state contracts for goods or services "it must do so in 
accordance with a system that is fair, equitable, transparent, competitive 
and cost-effective." This, the TAC argued. was relevant because: 
the capacity of the State to meet all of its constitutional obligations is ultimately 
dependent on the revenue it generates and the extent of its costs. Hence, the 
price at which mediCines are purchased is a crucial determinant in the capacity 
of the to meet its obligations, inter alia, to provide access to health care 
services. 
The TACs legal argument was that the measures contemplated by sec-
tions 15C, 22F & G, were ration~lly related to the 'pOSitive duty' on the 
state to protect and promote life " and dignity, and to improve access to 
health care services. Put another way, "if the state were to stand by when 
efficacious drugs for the treatment of HIV/AIDS and associated infections 
are placed beyond the reach of most people in this country, it would 
ignore a profound threat to the lives of millions of South Africans, .. ,,75 
The Heads of Argument also pointed out that the rights the PMA claim-
ed to have been violated were 'for the most part': 
fundamental rights which are afforded the weakest level of protection in the Bill 
of Rights, Sections 9( I)' 22 and 25( I) are enforceable only by rationality review 
70 Ibid, paragraphs 4 J ·56, 
71 AC, Heads of Argument. para 4,6. 
72 Ibid, 2.15.5. 
73 Ibid. 3. J 4 - 3. J 7, 
741bid,3.1S-3.24. 
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and therefore offer the applicams no more than the general ration-
ality review they can invoke under section I (c). 
On section 15C (parallel importation). the Heads adopted a slightly differ-
ent approach. again indicative of the political and legal independence of 
the TAC from the government. From the outset, the T AC (and privately 
many others) had recognised that 15C's weakness was its imprecise 
formulation. Therefore, on March 6th Advocate Chaskalson, counsel for 
the TAC, had informed the Judge that should the defence of the rationality 
of this clause be unsuccessful. the T AC would not mount an argument of 
"justification"n Initially this caused some shock with the government -
who perceived that the T AC was surrendering one of the most im portant 
parts of the Act. However. the proposals made in the final Heads of Ar-
gument made it clear that this was not the case. The TAC stoutly defended 
the rationality of 15C but offered that, should the Court decide otherwise, 
there were less drastic alternatives than striking the whole paragraph 
down. "Three remedial possibilities present themselves: 
9.6.1 First, section I5C may be subject to actual severance by deleting sub-
paragraph (al 
9.6.2 Second, section 15C(a) may be subject to notional severance along the 
following lines 
Section 15C(a) is declared unconstitutional to the extem that the words "not· 
withstanding anything to the contrary contained in the Patems Act. 1978" shall 
not be construed to permit any derogation from the Patents Act other than par-
allel importation. 
9.6.3 Third, words may be read into section 15C(a) along the following lines: 
"Notwithstanding anything to the contrary comained in the Patents Act. 
1978, with parallel importation. 
Sadly, these arguments were never heard in open court. 
3 WHAT WAS ACHIEVED? 
Faced with this array of evidentiary. legal and public opposition, a number 
of member companies of the PMA balked. Unlike Macbeth who recog-
nised that he was "in blood stepped in so far that, should [ wade no more, 
returning were as cedious as go o'er" and chose to go on with his ram-
it seems the PMA realised that continuing could only worsen their 
situation and that there was a way back. 
The case resumed on April 18th amid rumours that members of the 
PMA were divided and that some of the larger companies were deter-
mined to withdraw and settle.
78 
This seemed to be confirmed by the 
76 Ibid. para 4.8. 
77 T AC. First Heads of Argument. 5th March 200 I 
78 The Sunday Times, April 2001. reported that UN Secretary General. Kofi Annan. had 
phoned PreSident Mbeki and told him that "he had five of the biggest drug companies 
in [he world knocking on his door. asking him [0 help [hem untangle themselves from a 
three-year court battle with the SA government ... The case had been deeply 
to the pharmaceutical industry. casting it in the role of evil empire trying to thwart 










































LAW. DEMOCRACY &. DEVELOPMENT 
appearance of an additional legal team in court on behalf of some PMA 
members. An immediate request for an adjournment was made by the 
PMA. Then, on April 19th 2001. after 24 hours of intensive negotiations 
between pharmaceutical companies, who were split on the issue of aban-
doning the case, the PMA's legal team announced to Judge Ngoepe that its 
clients were unconditionally withdrawing their case against the govern-
ment and that all costs (except those of the amicus) would be borne by the 
applicants. 
The packed court erupted into spontaneous applause, again reminiscent 
of the conclusion of political trials in the 1980's, As activists celebrated, 
sang and toyi-toyied in the court room, the PMA and its legal team quietly 
left the room, 
However, within a matter of hours, various observers and organisations 
were beginning to question what concretely had been achieved in com-
pelling the PMA to withdraw. Skeptics of the 'victory' pointed to the fact 
that the PMA withdrawal meant that there would be no binding legal 
precedent in the form of a judgment, Others correctly pointed to the 
government's defence of section 15(C) in its Heads of Argument, as a 
mechanism solely for use for parallel importation of medicines: 
It is not the [Government's] intention to render nugatory the patent and other 
intellectual rights of the Applicants, but rather to activate the principle of ex-
haustion by importing more affordable genuine medicines placed by the Appli-
cants or their subsidiaries, or licensees on other markets 7" 
This, they argued, was a retreat from asserting its rights to use compul-
sory licencing, 
At the press conference called by the Minister of Health later the same 
day, much of the focus of media questions was on whether the Minister 
would now use the powers given to her by the Act to import generic anti-
retroviral medicines, This line of questioning betrayed a lack of knowledge 
of the compromise referred to above, The Minister's response was to pour 
cold water on the ebullient mood by stating categorically that it was not 
government policy to use antiretroviral medicines - nor would it be for 
the foreseeable future. A slightly more conCiliatory approach was adopted 
by Dr Ntsaluba, the Director General. 
But despite this there is no doubt that the TAC amicus and the interna-
tional campaign achieved a great deal. A three-year legal battle had dis-
solved, freeing the government to implement the Act. Internationally, the 
intense focus on medicines, prices, patents and rights to health greatly 
broadened the support-base of an incipient movement that seeks to treat 
health as a human right and to promote the idea that commodities such 
as medicines, that are essential for health, should be treated differently 
under patent law to commodities that do not have any intrinsic link to 
human dignity and well-being, This conviction undoubtedly had an impact 
on the negotiations around TRIPS which took place at the World Trade 
Organisation's (WTO) Ministerial Conference in Doha in November 2001 
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The Declaration on TRIPS (which recognises that "Each member has the 
right to grant compulsory licences") reflects the greater confidence of 
developing countries to defend rights to health against incursions by 
multi-national companies based on their interpretation of trade rules. so 
On another level, it provided proof that the world's most powerful 
multi-national companies are not invincible and can be brought to ac-
count by well researched, well argued mobilisations. This lesson will 
undoubtedly inspire other social struggles. 
At a national level, the TAC's campaign against the PMA deepened and 
broadened civil societies' understanding of certain aspects of socio-
economic rights and its ability to mobilise around these questions. It 
provided an important example of relationships that can be built between 
lawyers, doctors and a range of other interested parties. For example, it 
poses the question as to whether, if a similar campaign were mobilised 
around other important legal struggles such as the one that led to a 
Constitutional Court judgment on rights of access to land and housing in 
2000" there wouldn't be greater impetus for turning significant and 
symbolic legal rulings into bricks, mortar and stone. 
Finally, the court case brought a number of tangible and real benefits 
for people in need of medicines. including people living with HIV. As 
already mentioned, international pressure on the pharmaceutical compa-
nies brought down the price of a basket of antiretrovirals, making these 
medicines available in the private sector for a third of their cost of six 
months before. Potentially, this means that South Africa could expand the 
number of people benefiting from the use of these medicines from 
roughly 10 000 to ± 150 000. In addition to this, the sections of the Act 
dealing with generic substitution will bring about great savings to the 
ordinary consumer of medicines - estimated by some to be in the region 
of R2 billion per year. 
The previously uncontrollable monopoly of the pharmaceutical compa-
nies in South Africa has been weakened and they must now operate within 
a legal framework that exercises some control over prices and has broken 
[he chain of perverse incentives that previously kept medicine prices high. 
On June 1 st, the government published the regulations that must ac-
company the Act and it is expected that the Act will be brought into force 
by the end of 2001 . 
Of course. the campaign did not achieve everything. Access of very 
poor people to antiretrovirals remains dependent upon furrher price 
reductions and a change in government policy. But even here, the ground 
80 Declaration on the TRIPS Agreement and Public Health. Ministerial Conference. Fourth 
Session, (WT/MIN(O I )/DEC/W/2) 
81 Government of the Republic of South Africa v Irene Groocboom and ochers 2000 (1) SA 46 
(CC). 
82 The Sunday Times. April 22 200 I. reported "South Africans are set to benefit to the tune 
of R2.5 billion ($280 million) in a radical overhaul of the medicines industry ... Figures 
released on Friday by IMS South Africa. a pharmaceutical research company, show that 
South Africa spent R6.9 billion on branded medicines [in 2000] compared to R970 mil-
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has shifted. In its Replying Affidavit to the PMA's Answering Affidavit to 
TAC, the Director General of the Health Department, deposing on behalf 
of the government, states repeatedly under oath that affordability is the 
sole barrier to use of antiretrovirals. For example, at paragraph 40.1 he 
states: 
I dispute that cost considerations are not the main or the major obsta-
cles preventing the use of anti-retroviral medicines in the state and public 
sector. 
At paragraph 61 .1 : 
... the non-use of antiretroviral medicine in the publiC sector is clearly due to 
its unaffordability. 
At paragraph 66: 
It is price that prevents the use of anti-retroviral medicines in the public sector. 
These unambiguous admissions have laid the foundations for the next 
stage of the TAe's mobilisation as well as for further litigation. Access to 
antiretrovirals - as part of a greatly improved continuum of health care 
is vital to preserve and improve the Jives of hundreds of thousands of 
people with H!V. If the T AC and its allies are able to bring prices into the 
realm of affordability for the public sector, it will be impossible for gov-
ernment to sustain its current catalogue of excuses, largely brought for-
ward to mask the ideological opposition of the PreSidency, to the use of 
these medicines. 
A court application for a compulsory licence repeating many of the ar-
guments brought by the TAC in the PMA matter will soon be launched. It 
will commence from a much stronger base in the light of the role of the 
amicus curiae and its allies in this case. 
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Appendix 1 
Table J: Chronology of key dates The Battle in the Courts 
Date (200t) 
15 & 16 January TAe's National Executive Committee meets in Cape Town. 
26 January TAe's letter to ApplIcants and Respondents seeking 
admIssion as Amicus Curiae. 
6 February Reply to TAC from PMA's attorneys. 
14 February Reply to TAC From the government. 
16 February TAC Founding AffidaVit and Notice of Motion served on 
parties and flied with Pretoria High Court. 
22 February Answering affidavit of PMA, Deeb 
1 March I Amicus's Replying Affidavit to PMA. 
5 March Argument begins in the Pretoria High Court. 
6th March Judge Bernard Ngoepe admits TAC as amicus and instructs 
AppliCants and Respondents to reply to allegations made 
in TAe's Founding Affidavit. The case is postponed to 18 
April I 
28 March PMA's Answering Affidavit to TAe's Founding Affidavit is 
filed. i 
10 April TAC and the government's Replying Affidavits to the PMA 
are filed. 
17 April TAe's Heads of Argument are filed with the Court and 
served on parties. 
18 April The court case resumes and is quickly adjourned at the 
request of the PMA. 
19 April The PMA withdraws the matter unconditionally. 
I June The government publishes a Government Gazette with 
draft Regulations for the Act 
Table 2: Chronology of key dates - The Battle for Public Opinion 
Date 
15 & 16 January TAe's National Executive Committee. Press conFerence calls 
for national and International day of action on 5 March. 
18 February TAC leads March of I 000 people to Parliament in Cape 
Town. 
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Table 2: Chronology of key dates The Battle for Public Opinion 
I March TAC, MSF, Oxfam, COSATU International press conference. 
Poster published in press calling for people to join the 
demonstration 
4 March TAC and COSATU night vigil in Church Square, Pretoria. 
5 March Global day of action: demonstrations in 30 cities world-
wide; 250 organisations call for case to be withdrawn. 
5 March 5 000 people march past the Pretoria Court to US 
Embassy led by church and trade union National 
and international demonstrations are headline news 
world-wide. 
6 March COSA TU pickets outside Court continue. 
European Union passes resolution calling for PMA to 
withdraw. 
18 April Court case resumes. Pickets held outside Court. Court room 
packed with TAC volunteers, ANC members, trade union 
leaders. MSF hands over petition with 250 000 names to 
PMA. 
19 April PMA withdraws matter. Headline news world-Wide. TAC, 
Oxfam and MSF hold international press conference. 
Appendix 2 
TAC Internal Memo, April 2001 
CURRENT OFFERS ON ARVS MADE TO THE SA GOVERNMENT 
FOR USE IN THE PUBLIC SECTOR. 
Notes 
This list is based on documentation contained in the PMA Answering Affida-
vit to TAG: It does not include prices offered by ClPLA 
Although the offers are made to the public sector - and further price 
reductions can still be brought about by compulsory licensing and activist 
pressure - a successful campaign to extend these price offers to the private 
sector, could very quickly make access to antiretrovirals affordable to 
many thousands more people, particularly those with a middle income or 
who are members of medical aid schemes. TAC could fulfill its mission to 
save lives. 
Essentially what they reveal is that a range of combinations of triple 
therapy (2 NRTls and one PI) could be immediately available at between 
R6 000 and R8000 per year (or R500 to R660 per month). In this price 
range the 'Right to Care Initiative' calculates that up to 150000 people 
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Nucleoside Reverse Transcriptase Inhibitors: 
Didanosine & (Videx; ddI) and Stavudine (Zerit; d4T): offered together for 
$ 1 per day (approx R8/day; R2 ,920 per annum) 
Company: BMS 
Zidovudine (AZTI Retrovir) 1,02 pounds I day (approx RIO per day; 
R3 650 per annum); 
Lamivudine (3TC, Epivir) 40 pence per day (appro x R4 per day; RI 460 
per annum); 
Combivir (AZT & 3TC) 1.30 pounds per day (approx R 13 per day: R4 745 
per annum) 
Company: Glaxo Wellcome 
Non-Nucleoside Reverse Transcriptase Inhibitors: 
Efavirenz (Stocrin) $ 1.30 per day ($500 per annum) (approx RIO per day; 
R3 650 per annum); 
Company: MSD 
Nevirapine (Viramune) free for MTCT 
Company: Boehringer lngelheim 
Protease Inhibitors: 
Indanivir (Crixivan) $ 1.60 per day ($600 per annum) (approx R8 per day; 
R2 920 per annum); 
Company: MSD 
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